Pembrolizumab (anti-PD-1)

Catalog No.A2005        Batch: A200506

Print

Technical Data

CAS No. 1374853-91-4
Formulation PBS buffer, pH 7.2
Isotype Human IgG4
Source CHO cells
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Purity 99%
Protein concentration 6.1mg/ml
Endotoxin Level ＜1EU/mg

Biological Activity

Description Pembrolizumab (anti-PD-1) is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.
Targets
PD-1 [1]
(Cell-free assay)
In vitro

The level of LDH and apoptosis are significantly higher in those treated with dexamethasone plus PD1 inhibitor pembrolizumab than other groups.[1]
In vivo

Pembrolizumab and dexamethasone synergistically suppress tumor growth of pancreatic cancer in vivo.[1]

Protocol (Only for Reference)

Cell Assay:

  • Cancer cells were incubated with dexamethasone for 48 h followed by co-cultured with PBMCs with effector/target ratio of 10:1 and the addition of PD1 inhibitor (pembrolizumab; 5 μg/mL) for another 48 h. LDH level was detected.
Animal Study:

  • Animal Models: Immune reconstituted NOD/SCID mice model
    Dosages: 5 mg/kg
    Administration: i.v.
    Reference: [1]
     

Selleck's Pembrolizumab (anti-PD-1) has been cited by 63 publications

Increased PD-1 expression in livers associated with PD-1-antibody-induced hepatotoxicity [ BMC Immunol, 2025, 26(1):4] PubMed: 39844069
Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial [ Nat Med, 2024, 10.1038/s41591-024-02824-y] PubMed: 38374347
Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer [ Cancer Cell, 2024, 42(12):2045-2063.e10] PubMed: 39658541
The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation [ Cell Mol Immunol, 2024, 21(1):60-79] PubMed: 38062129
Multi-omic profiling reveals the endogenous and neoplastic responses to immunotherapies in cutaneous T cell lymphoma [ Cell Rep Med, 2024, S2666-3791(24)00196-4] PubMed: 38670099
Miltefosine reinvigorates exhausted T cells by targeting their bioenergetic state [ Cell Rep Med, 2024, 5(12):101869] PubMed: 39657666
Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation [ J Immunother Cancer, 2024, 12(5)e008669] PubMed: 38702145
Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia [ Pharmacol Res, 2024, 199:107048] PubMed: 38145833
Deprivation of methionine inhibits osteosarcoma growth and metastasis via C1orf112-mediated regulation of mitochondrial functions [ Cell Death Dis, 2024, 15(5):349] PubMed: 38769167
VentX promotes tumor specific immunity and efficacy of immune checkpoint inhibitors [ iScience, 2024, 27(1):108731] PubMed: 38299030

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage.
We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.